Applications of poly(ethylene oxide) in controlled release tablet systems: A review

Drug Development and Industrial Pharmacy

Volumn 40, Issue 7, 2014, Pages 845-851

  Ma, Lulu ^a,b   Deng, Li ^a   Chen, Jianming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

Author keywords

Bioadhesive hydrophilic matrix; Commercial product; Controlled release tablet; Matrix tablet; Osmotic pump tablet; PEO; Physicochemical properties

Indexed keywords

MACROGOL; DELAYED RELEASE FORMULATION; DRUG CARRIER; MACROGOL DERIVATIVE; TABLET;

CONTROLLED RELEASE FORMULATION; DISSOLUTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; FIRST PASS EFFECT; GLASS TRANSITION TEMPERATURE; HYDROPHILICITY; MATRIX TABLET; MOLECULAR WEIGHT; OSMOTIC PRESSURE; PH; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; REVIEW; TABLET FORMULATION; ADHESION; ADMINISTRATION AND DOSAGE; CHEMICAL PHENOMENA; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG RELEASE; TABLET; VISCOSITY;

ADHESIVENESS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG LIBERATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; TABLETS; VISCOSITY;

EID: 84902292310     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.831438     Document Type: Review

References (77)

1. Kim CJ. Effects of drug solubility, drug loading, and polymer molecular weight on drug release from Polyox tablets. Drug Dev Ind Pharm 1998;24: 645-51.
2. Kim CJ. Drug release from compressed hydrophilic POLYOX-WSR tablets. J Pharm Sci 1995;84: 303-6.
3. Wu N, Wang LS, Tan DC, et al. Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights. J Contr Rel 2005;102: 569-81.
4. Maggi L, Segale L, Torre ML, et al. Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study. Biomaterials 2002;23: 1113-19.
5. Molina I, Li S, Martinez MB, Vert M. Protein release from physically crosslinked hydrogels of the PLA/PEO/PLA triblock copolymer-type. Biomaterials 2001;22: 363-9.
6. Shah AP, Bhandary SR. POLYOX (Polyethylene Oxide) - applications in pharma industry. Pharmainfo.net; 2010. Available from: http://www.pharmainfo. net/reviews/polyox-polyethyleneoxide- applications-pharma-industry.
7. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001;48: 139-57.
8. Wu C. Simulated glass transition of poly(ethylene oxide) bulk and film: a comparative study. J Phys Chem B 2011;115: 11044-52.
9. Palmer D, Levina M, Nokhodchi A, et al. The influence of sodium carboxymethylcellulose on drug release from polyethylene oxide extended release matrices. AAPS PharmSciTech 2011;12: 862-71.
10. Shah R, Patel S, Patel H, et al. Formulation development of Carvedilol compression coated tablet. Pharm Dev Technol 2011; 18: 906-15.
11. Crowley MM, Zhang F, Koleng JJ, Mcginity JW. Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion. Biomaterials 2002;23: 4241-8.
12. Pinto JF, Wunder KF, Okoloekwe A. Evaluation of the potential use of poly(ethylene oxide) as tablet- and extrudate-forming material. AAPS J 2004;6: 17-26.
13. Leskinen JT, Hakulinen MA, Kuosmanen M, et al. Monitoring of swelling of hydrophilic polymer matrix tablets by ultrasound techniques. Int J Pharm 2011;404: 142-7.
14. Li H, Hardy RJ, Gu X. Effect of drug solubility on polymer hydration and drug dissolution from polyethylene oxide (PEO) matrix tablets. AAPS PharmSciTech 2008;9: 437-43.
15. Li H, Gu X. Correlation between drug dissolution and polymer hydration: a study using texture analysis. Int J Pharm 2007;342: 18-25.
16. Korner A, Piculell L, Iselau F, et al. Influence of different polymer types on the overall release mechanism in hydrophilic matrix tablets. Molecules 2009;14: 2699-716.
17. Shin S, Choi du H, Truong NK, et al. Time-oriented experimental design method to optimize hydrophilic matrix formulations with gelation kinetics and drug release profiles. Int J Pharm 2011;407: 53-62.
18. Harland RS, Gazzaniga A, Sangalli ME, et al. Drug/polymer matrix swelling and dissolution. Pharm Res 1988;5: 488-94.
19. Colombo P, Bettini R, Massimo G, et al. Drug diffusion front movement is important in drug release control from swellable matrix tablets. J Pharm Sci 1995;84: 991-7.
20. Korner A, Larsson A, Andersson A, Piculell L. Swelling and polymer erosion for poly(ethylene oxide) tablets of different molecular weights polydispersities. J Pharm Sci 2010;99: 1225-38.
21. Apicella A, Cappello B, Del nobile MA, et al. Poly(ethylene oxide) (peo) and different molecular weight peo blends monolithic devices for drug release. Biomaterials 1993;14: 83-90.
22. Miro A, Quaglia F, Giannini L, et al. Drug/cyclodextrin solid systems in the design of hydrophilic matrices: a strategy to modulate drug delivery rate. Curr Drug Deliv 2006;3: 373-8.
23. Cappello B, De Rosa G, Giannini L, et al. Cyclodextrin-containing poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: potential as buccal delivery system. Int J Pharm 2006;319: 63-70.
24. Tajiri T, Morita S, Sakamoto R, et al. Release mechanisms of acetaminophen from polyethylene oxide/polyethylene glycol matrix tablets utilizing magnetic resonance imaging. Int J Pharm 2010;395: 147-53.
25. Hong SI, Oh SY. Dissolution kinetics and physical characterization of three-layered tablet with poly(ethylene oxide) core matrix capped by Carbopol. Int J Pharm 2008;356: 121-9.
26. Kim CJ. Release kinetics of coated, donut-shaped tablets for water soluble drugs. Eur J Pharm Sci 1999;7: 237-42.
27. Korner A, Larsson A, Piculell L, Wittgren B. Molecular information on the dissolution of polydisperse polymers: mixtures of long and short poly(ethylene oxide). J Phys Chem B 2005;109: 11530-7.
28. Petrovic J, Jockovic J, Ibric S, Duric Z. Modelling of diclofenac sodium diffusion from swellable and water-soluble polyethylene oxide matrices. J Pharm Pharmacol 2009;61: 1449-56.
29. Park JS, Shim JY, Nguyen KV, et al. A pharma-robust design method to investigate the effect of PEG and PEO on matrix tablets. Int J Pharm 2010;393: 79-87.
30. Sako K, Nakashima H, Sawada T, Fukui M. Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Pharm Res 1996;13: 594-8.
31. Bagchi S, Li W, Plakogiannis F. Optimization and prediction of drug release from matrix tablets using response surface methodology and near infrared chemical imaging. Pharm Dev Technol 2012;17: 398-406.
32. Quinten T, De beer T, Almeida A, et al. Development and evaluation of injection-molded sustained-release tablets containing ethylcellulose and polyethylene oxide. Drug Dev Ind Pharm 2011;37: 149-59.
33. Cha KH, Park J, Cho W, et al. Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia. Arch Pharm Res 2009;32: 1593-8.
34. Di Colo G, Falchi S, Zambito Y. In vitro evaluation of a system for pH-controlled peroral delivery of metformin. J Control Release 2002;80: 119-28.
35. Peppas NA, Sahlin JJ. Hydrogels as mucoadhesive and bioadhesive materials: a review. Biomaterials 1996;17: 1553-61.
36. Forstner JF, Jabbal I, Forstner GG. Goblet cell mucin of rat small intestine. Chemical and physical characterization. Can J Biochem 1973;51: 1154-66.
37. Tiwari D, Goldman D, Sause R, Madan PL. Evaluation of polyoxyethylene homopolymers for buccal bioadhesive drug delivery device formulations. AAPS PharmSci 1999;1:E13.
38. Bottenberg P, Cleymaet R, De muynck C, et al. Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. J Pharm Pharmacol 1991;43: 457-64.
39. Sadeghi AM, Avadi MR, Ejtemaimehr S, et al. Development of a gas empowered drug delivery system for peptide delivery in the small intestine. J Contr Rel 2009;134: 11-17.
40. El-Samaligy MS, Yahia SA, Basalious EB. Formulation and evaluation of diclofenac sodium buccoadhesive discs. Int J Pharm 2004;286: 27-39.
41. Miro A, Rondinone A, Nappi A, et al. Modulation of release rate and barrier transport of Diclofenac incorporated in hydrophilic matrices: role of cyclodextrins and implications in oral drug delivery. Eur J Pharm Biopharm 2009;72: 76-82.
42. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv 2006;3: 217-33.
43. Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm 2004;30: 1019-28.
44. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 1996;136: 117-39.
45. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm 2002;241: 279-92.
46. Meka L, Kesavan B, Chinnala KM, et al. Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation. AAPS PharmSciTech 2008;9: 612-19.
47. Cooreman MP, Krausgrill P, Hengels KJ. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother 1993;37: 1506-9.
48. Liu Q, Fassihi R. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm 2008;348: 27-34.
49. Needleman IG, Martin GP, Smales FC. Characterisation of bioadhesives for periodontal and oral mucosal drug delivery. J Clin Periodontol 1998;25: 74-82.
50. Kapil R, Kapoor DN, Dhawan S. Flow, compressive, and bioadhesive properties of various blends of poly(ethylene oxide). Drug Dev Ind Pharm 2010;36: 45-55.
51. Vaghani SS, Patel SG, Jivani RR, et al. Design and optimization of a stomach-specific drug delivery system of repaglinide: application of simplex lattice design. Pharm Dev Technol 2012;17: 55-65.
52. Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 2000;26: 695-708.
53. Park SJ, Kim KS, Kim SH. Effect of poly(ethylene oxide) on the release behaviors of poly(epsilon-caprolactone) microcapsules containing erythromycin. Colloids Surf B Biointerfaces 2005;43: 238-44.
54. Rose S, Nelson JF. A continuous long-term injector. Aust J Exp Biol Med Sci 1955;33: 415-19.
55. Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64: 1987-91.
56. Swanson DR, Barclay BL, Wong PSL, Theeuwes F. Nifedipine gastrointestinal therapeutic system. Am J Med 1987;83: 3-9.
57. Liu L, Khang G, Rhee JM, Lee HB. Monolithic osmotic tablet system for nifedipine delivery. J Contr Rel 2000a;67: 309-22.
58. Turner S, Federici C, Hite M, Fassihi R. Formulation development and human in vitro-in vivo correlation for a novel, monolithic controlled-release matrix system of high load and highly watersoluble drug niacin. Drug Dev Ind Pharm 2004;30: 797-807.
59. Liu L, Ku J, Khang G, et al. Nifedipine controlled delivery by sandwiched osmotic tablet system. J Contr Rel 2000b;68: 145-56.
60. Liu L, Khang G, Rhee JM, Lee H B. Sandwiched osmotic tablet core for nifedipine controlled delivery. Biomed Mater Eng 1999;9: 297-310.
61. Kumaravelrajan R, Narayanan N, Suba V, Bhaskar K. Simultaneous delivery of Nifedipine and Metoprolol tartarate using sandwiched osmotic pump tablet system. Int J Pharm 2010;399: 60-70.
62. Wang X, Nie SF, Li W, et al. Studies on bi-layer osmotic pump tablets of water-insoluble allopurinol with large dose: in vitro and in vivo. Drug Dev Ind Pharm 2007;33: 1024-9.
63. Wang C, Chen F, Heng PW, et al. A novel time-controlled release system based on drug-resin complexes and elementary osmotic pump. Chem Pharm Bull (Tokyo) 2008;56: 457-63.
64. Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct 2009;6:8.
65. Letter TM. In brief: immediate-release oxycodone (Oxecta) for pain. The Medical Letter. Available from: http://secure.medicalletter.org/ w1385d [last accessed 28 April 2013].
66. Depomed. About GRALISE. Depomed. Available from: http://www.gralise.com/ patient/about [last accessed 28 April 2013].
67. Santarus. glumetza® [Online]. RxList. Available from: http://www.rxlist.com/glumetza-drug.htm [last accessed 28 April 2013].
68. Merck. Janumet® XR. Rxlist. Available from: http://www.rxlist. com/janumet-xr-drug.htm [last accessed 28 April 2013].
69. Glaxosmithkline. DynaCirc CR®. RxList. Available from: http://www.rxlist.com/dynacirc-cr-drug.htm [last accessed 28 April 2013].
70. Pfizer. Cardura® XL. RxList. Available from: http://www.rxlist. com/cardura-xl-drug.htm [last accessed 28 April 2013].
71. Pfizer. glucotrol xl®. RxList. Available from: http://www.rxlist. com/glucotrol-xl-drug.htm [last accessed 28 April 2013].
72. Pfizer. procardia xl®. RxList. Available from: http://www.rxlist. com/procardia-xl-drug.htm [last accessed 28 April 2013].
73. Pfizer. covera-hs®. RxList. Available from: http://www.rxlist.com/ covera-hs-drug.htm [last accessed 28 April 2013].
74. Purdue. OxyContin®. RxList. Available from: http://www.rxlist. com/oxycontin-drug.htm [last accessed 27 April 2013].
75. Elzweig M. OPANA: a brief history. NewYorkPress. Available from: http://nypress.com/opana-a-brief-history/ [last accessed April 2013].
76. Jassen. NUCYNTA®ER. RxList. [last accessed 28 April 2013].
77. Varma M, Singla AK, Dhawan S. Release of diltiazem hydrochloride from hydrophilic matrices of polyethylene oxide and carbopol. Drug Dev Ind Pharm 2004;30: 545-53.